Personality
4
Open
6
Cons
3
Extr
5
Agre
4
Neur
FDC
Healthcare · Mid Cap
Mature Stable · Hierarchical
About
Mohan A. Chandavarkar is the Managing Director of FDC, a Mid Cap company in the Healthcare sector with a market cap of ₹6K Cr. A Pragmatic leader with 63 years of experience, he is known for consensus-driven decision-making and organic builder strategy. Maintains a conservative, steady-state growth strategy focusing on domestic pharmaceutical stability and established brand equity.
FAQ
What is Mohan A. Chandavarkar's leadership style?
Mohan A. Chandavarkar is classified as a Pragmatic leader. He is consensus-driven in decision-making, with a dynasty builder motivation and steady-marathon pace of execution.
What is Mohan A. Chandavarkar's educational background?
Mohan A. Chandavarkar holds a B.S. (Hons.) from Bombay University.
Who is the CEO of FDC?
Mohan A. Chandavarkar is the Managing Director of FDC. He has been with the company for 63 years and in the current role for 26 years.
Leadership DNA
ArchetypePragmatic
MotivationDynasty Builder
CrisisSteady Hand
DecisionConsensus-Driven
GrowthOrganic Builder
PeopleRelationship Led
InnovationTraditionalist
PaceSteady-Marathon
PurposeProfit-Pure
CustomerMass-Consumer
EmployerSteady Employer
BrandTrusted
FocusOperational Excellence
OrientationDeep Specialist
Leadership Evidence
“Maintains a conservative, steady-state growth strategy focusing on domestic pharmaceutical stability and established brand equity.”
⚡ Crisis●●●●○
FDC has historically maintained a conservative, debt-free balance sheet and steady operational focus rather than engaging in drastic restructuring or aggressive market-share-at-all-costs maneuvers during downturns.
🎯 Motivation●●●●●
As part of the founding Chandavarkar family, Mohan has focused on long-term stewardship and continuity of the family-led pharmaceutical legacy.
👥 People●●●●○
FDC is known for a stable, long-tenured workforce and a culture that prioritizes internal loyalty and institutional memory over aggressive lateral hiring.
📈 Growth●●●●●
FDC's growth has been consistently driven by internal R&D, manufacturing excellence, and deepening its presence in established therapeutic segments like ophthalmology and stomatology.
💡 Innovation●●●●○
FDC relies on its long-standing legacy brands like Electral and Zifi, focusing on steady manufacturing and market penetration rather than pioneering new drug discovery.
🏃 Pace●●●●○
The company maintains a predictable, process-driven operational rhythm characteristic of a mature, family-promoted pharmaceutical firm.
🌱 Purpose●●●○○
The company operates primarily as a commercial pharmaceutical entity with standard CSR compliance rather than a mission-led social enterprise.
🏷️ Brand●●●●○
FDC has built significant institutional credibility over decades, with its products being household staples relied upon for safety and consistent quality.
🤝 Customer●●●●○
FDC has a strong retail presence with household names like Electral, which are widely distributed and consumed by the general public.
💼 Employer●●●○○
As a mature, promoter-led organization, FDC is known for stability and long-term employee retention rather than high-octane startup-style growth.
📋 Mandate
Needs to move beyond legacy product dependence by investing in R&D and niche therapeutic segment expansion.
🏢 Culture●●●○○
Long-standing family-led pharmaceutical firm with conservative management style and strong adherence to traditional corporate structures.
Financials
Revenue FY25₹2K Cr
PAT FY25₹267 Cr
Rev CAGR 5Y11.4%
OPM12.9%
NPM12.7%
ROE11.7%
ROCE11.5%
P/E26.5
Fwd P/E15.1
P/B2.4
D/E0.9
Promoter70%
Institutional7.5%
Mkt Cap₹6K Cr
Compensation
To Be Published
Data being verified from audited reports
